Vir Biotechnology Inc
NASDAQ:VIR
Vir Biotechnology Inc
Revenue
Vir Biotechnology Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Vir Biotechnology Inc
NASDAQ:VIR
|
Revenue
$86.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Vir Biotechnology Inc's Revenue?
Revenue
86.2m
USD
Based on the financial report for Dec 31, 2023, Vir Biotechnology Inc's Revenue amounts to 86.2m USD.
What is Vir Biotechnology Inc's Revenue growth rate?
Revenue CAGR 5Y
52%
Over the last year, the Revenue growth was -95%. The average annual Revenue growth rates for Vir Biotechnology Inc have been 4% over the past three years , 52% over the past five years .